Pulse Biosciences Announces Positive Results For CellFX NsPFA 360 Cardiac Catheter Study; Stock Up

Pulse Biosciences, Inc. (PLSE), Wednesday announced positive results from the 60-day post-procedure evaluations of four initial patients with atrial fibrillation in the CellFX nsPFA 360 Cardiac Catheter First-in-Human Feasibility Study.

Related Keywords

Vivek Reddy , Arrhythmia Services , Nasdaq , Pulse Biosciences Inc , Pulse Biosciences , Catheter First In Human Feasibility , Cardiac Arrhythmia Services , Mount Sinai Fuster Heart Hospital ,